Status:

COMPLETED

In Situ Immune Parameters and Their Prognostic Role on the Survival of Patients With Glioblastoma

Lead Sponsor:

Centre Georges Francois Leclerc

Conditions:

Glioblastoma

Eligibility:

All Genders

18-75 years

Brief Summary

Glioblastoma (GBM) is the most frequent brain tumor. Currently survival is poor and few treatments are available. Recent data show that there is no immune privilege of the central nervous system (CNS)...

Detailed Description

Primary objective : The primary objective is to determine for each of the 3 molecular subtypes of glioblastoma the predictive performance on 1-year overall survival of in situ immune parameters Seco...

Eligibility Criteria

Inclusion

  • Patients with newly diagnosed, brain tumor
  • Gross or near total resection of the contrast-enhancing tumor mass decides by the neurosurgeron.
  • Subjects ≥18 and ≤75 years of age at surgery
  • Patients must be able to understand and sign the informed consent documents indicating that they are aware of the investigational nature of this study.
  • Confirmation of the diagnosis of grade IV GBM by the local pathologist with an independent neuropathologist who will review this diagnosis
  • Primary therapy must consist of surgical resection with the intent for a gross or near total resection of the contrast-enhancing tumor mass, followed by conventional external beam radiation therapy and concurrent temozolomide chemotherapy.
  • Tumor biopsy for biological analysis has to be performed before using ultrasonic surgery

Exclusion

  • Patient with other type of primary brain tumor or metastases
  • Patients with only biopsy performed for the diagnosis
  • Subjects under guardianship, curatorship or judicial protection
  • Female subjects who are pregnant or breast-feeding

Key Trial Info

Start Date :

September 13 2020

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

September 14 2024

Estimated Enrollment :

160 Patients enrolled

Trial Details

Trial ID

NCT03481231

Start Date

September 13 2020

End Date

September 14 2024

Last Update

February 17 2025

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Centre Georges François Leclerc

Dijon, France, 21000

2

CHU de DIJON

Dijon, France, 21000

3

CHU de Nantes

Saint-Herblain, France, 44800

4

Università di Florence

Florence, Italy